Animal-derived pharmaceutical proteins.
Livestock animals have made a significant contribution to human health and well-being throughout humankind's history. A significant contribution of farm animals to human health are the longstanding use of bovine and porcine for production of insulin (for treatment of diabetes), gelatin (for pharmaceutical and other purposes), as well as horse and sheep antibody against natural venoms, toxins, drugs and microbial peptides. Gelatin being the biggest animal protein consumed in human health, follows with antibodies fragments. The chronic problem of animal-derived therapeutics, especially those of high molecular weight, is the immunogenicity induction in addition to their biosafety. However, the invertebrates and lower vertebrates donate the human being a several crucial emergency saving life small-peptides or their analogs such as Refludan, Prialt, Exendin. Not only, but the farm animals are enormously using as models for novel surgical strategies, testing of biodegradable implants and sources of tissue replacements, such as skin and heart valves. Recently, they are being harnessing as bioreactor for production of biopharmaceutical related products through gene farming with efficiency far greater than any conventional microbial or cell-culture production systems. Only 16 transgenic cows would be covering the worldwide needs from human growth hormone. The transgenic, especially animal, technology would be solving a several biopharmaceutical products disadvantages, such as cost, biosafety, immunogenicity and the availability dimensions.
Redwan
el-Rashdy M
el-RM
Antibody Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, Mubarak City for Scientific Research and Technology Applications, New Borg El-Arab, Alexandria, Egypt. redwan1961@yahoo.com
D000818:Animals; D030801:Animals, Genetically Modified; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016466:CHO Cells; D002417:Cattle; D045744:Cell Line, Tumor; D006224:Cricetinae; D003412:Cricetulus; D005780:Gelatin / Q000737:chemistry; D006629:Hirudins; D007106:Immune Sera; D007116:Immunization, Passive / Q000379:methods*; D007328:Insulin / Q000627:therapeutic use; D004364:Pharmaceutical Preparations; D014176:Protein Biosynthesis; D011994:Recombinant Proteins / Q000627:therapeutic use; D013678:Technology, Pharmaceutical; D014688:Venoms / Q000276:immunology
D000906:Antibodies; D000911:Antibodies, Monoclonal; D006629:Hirudins; D007106:Immune Sera; D007328:Insulin; D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins; D014688:Venoms; D005780:Gelatin; C083544:lepirudin